Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
CXCL2 Biologics Sequence Review Report 2026: C-X-C motif chemokine 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CXCL2 Biologics Sequence Review Report 2026: C-X-C motif chemokine 2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CXCL2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IL1RN Biologics Sequence Review Report 2026: Interleukin-1 receptor antagonist protein Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IL1RN Biologics Sequence Review Report 2026: Interleukin-1 receptor antagonist protein Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of IL1RN protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD7 Biologics Sequence Review Report 2026: T-cell antigen CD7 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD7 Biologics Sequence Review Report 2026: T-cell antigen CD7 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD48 Biologics Sequence Review Report 2026: CD48 antigen Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD48 Biologics Sequence Review Report 2026: CD48 antigen Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD48 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGA5 Biologics Sequence Review Report 2026: Integrin alpha-5 Similarity and Patent-Risk Signals
8 min read
ITGA5 Biologics Sequence Review Report 2026: Integrin alpha-5 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGA5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGA2B Biologics Sequence Review Report 2026: Integrin alpha-IIb Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGA2B Biologics Sequence Review Report 2026: Integrin alpha-IIb Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGA2B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD3E Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD3 epsilon chain Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD3E Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD3 epsilon chain Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD3E protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD160 Biologics Sequence Review Report 2026: CD160 antigen Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD160 Biologics Sequence Review Report 2026: CD160 antigen Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD160 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TNFRSF6B Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 6B Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TNFRSF6B Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 6B Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of TNFRSF6B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FCGR3B Biologics Sequence Review Report 2026: Low affinity immunoglobulin gamma Fc region receptor III-B Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FCGR3B Biologics Sequence Review Report 2026: Low affinity immunoglobulin gamma Fc region receptor III-B Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FCGR3B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IL9 Biologics Sequence Review Report 2026: Interleukin-9 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IL9 Biologics Sequence Review Report 2026: Interleukin-9 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of IL9 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IL1R1 Biologics Sequence Review Report 2026: Interleukin-1 receptor type 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IL1R1 Biologics Sequence Review Report 2026: Interleukin-1 receptor type 1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of IL1R1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →